Abstract: The present invention relates to a process for the preparation of a conjugate, comprising a biological molecule, an enzymatic tag, a hydrophilic spacer, a linker and a lipophilic moiety using enzymatic coupling.

Abstract: The present invention relates to a process for the preparation of a solid pharmaceutical administration form comprising an amorphous solid dispersion using a 3D printing process. The process is a printing process that allows the production of a solid pharmaceutical solid administration form comprising an amorphous solid dispersion in an easy and flexible manner and the possibility to achieve fast disintegrating dosage forms with high drug loads.

Abstract: A vehicle radar system (110) that having a control unit (120) and a radar transceiver (130) that in turn including a controllable transmitter antenna arrangement (141). The control unit (120) is adapted to control the radar transceiver (130) to generate and transmit a radar signal (124), and receive a reflected radar signal (125). The control unit (120) is adapted to control the transmitter antenna arrangement (141) to generate a first antenna radiation pattern (160) for the transmitted radar signal (124), and to control the transmitter antenna arrangement (141) to generate a plurality of second antenna radiation patterns (161, 162, 163) for the transmitted radar signal (124). In a predetermined angular direction (?) is determined which second antenna radiation pattern (162) that provides the largest receive amplitude difference (?A2) between the first antenna radiation pattern (160) and the second antenna radiation patterns (161, 162, 163), and to choose that second antenna radiation pattern (162).

Abstract: The present invention relates to a pharmaceutical formulation of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol or pharmaceutically acceptable salt thereof, as well as a method of making same, as well as medical uses thereof.

Abstract: The present invention relates to a process for the preparation of a solid pharmaceutical administration form comprising mesoporous silica using a 3D printing process. The process is a printing process that allows the production of solid pharmaceutical administration forms comprising drug loaded mesoporous silica in an easy and flexible manner and in conformity with the high-quality standards required for the production of pharmaceutical.

Abstract: A pharmaceutical formulation has (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol or pharmaceutically acceptable salt thereof.

Abstract: A pharmaceutical formulation has (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol or pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a solid pharmaceutical preparation of 3-Fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1H-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl]-benzonitrile, a method of making same, and medical uses thereof.

Abstract: The present invention relates to a process for the preparation of a conjugate, comprising a biological molecule, an enzymatic tag, a hydrophilic spacer, a linker and a lipophilic moiety using enzymatic coupling.

Abstract: The present invention is directed to a process for the preparation of a coated solid pharmaceutical dosage form using 3D printing technology.

Abstract: A pharmaceutical formulation has (S)-[2-chloro-4-fluoro-5-(7-tnorpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol or pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a solid pharmaceutical preparation of 3-Fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1H-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl]-benzonitrile, a method of making same, and medical uses thereof.

Abstract: The invention relates to a therapeutically effective truncated survivin and its therapeutic use as vaccine in a liposomal preparation, wherein the survivin fragment is preferably gluconoylated, and said liposomal preparation elicits in-vivo anti-tumor activity. The invention is directed, in more detail, to a cancer vaccine comprising a fragment of human survivin that is specifically effective in conjunction with an lipid adjuvant. The invention relates in more detail to a liposomal vaccine delivery system comprising an active truncated survivin molecule as tumor antigen and a chiral cationic lipid, for example R-DOTAP acting as adjuvant, which is part of the liposome preparation, wherein the liposomal drug delivery system is optimized with regard to its lipid and adjuvant components, physical or physicochemical parameters, and the final therapeutic efficacy of the released truncated survivin molecules.

Abstract: The present invention relates to a lyophilized nanoemulsion comprising a lipophilic phase and one or more sucrose fatty acid esters, to the nanoemulsion which can be prepared from the lyophilized nanoemulsion by redispersion, and to a process for the preparation of the lyophilized nanoemulsion.

Abstract: The present invention relates to a lyophilised nanoemulsion comprising a lipophilic phase and one or more sucrose fatty acid esters, to the nanoemulsion which can be prepared from the lyophilised nanoemulsion by redispersion, and to a process for the preparation of the lyophilised nanoemulsion.